Showing results (51-60 of 2,229) with videos related to
Sort By:
Pageof 223
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Clinical utility of 99mTc-Sestamibi scintimammography in the management of equivocal breast lesionsConcetta De Cicco, Giuseppe Trifirò, Silvia Baio, et al.Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
The cytotoxicity of Scytosiphon lomentaria against HL-60 promyelocytic leukemia cellsSang-Cheol Kim, Soo-Young Park, Jae-Hee Hyoun, et al.Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2Walter D Y Quan, Francine M QuanCancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functionsIda Contasta, Anna Maria Berghella, Patrizia Pellegrini, et al.Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancerAnneli Schmitt, Peter Bernhardt, Ola Nilsson, et al.Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapyThomas D Harris, Shirley Kalogeropoulos, Tiffany Nguyen, et al.Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agentAsa Liljegren Sundberg, Anna Orlova, Alexander Bruskin, et al.Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
Modern management of differentiated thyroid cancerJason B Cohen, Judy E Kalinyak, I Ross McDougallCancer Biotherapy & Radiopharmaceuticals|November 25, 2003
A novel monoclonal antibody design for radioimmunotherapyAndres Forero, Ruby F Meredith, M B Khazaeli, et al.Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitroAstrid Capello, Eric P Krenning, Wout A P Breeman, et al.Pageof 223